Pharmacoeconomic review report Propiverine hydrochloride (Mictoryl/Mictoryl pediatric)
Propiverine modified-release formulation (Mictoryl, MR) and propiverine pediatric (Mictoryl Pediatric) are detrusor relaxant drugs with antimuscarinic and calcium-modulating properties indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patie...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Series: | Common drug review clinical review report.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268406719 |
| Summary: | Propiverine modified-release formulation (Mictoryl, MR) and propiverine pediatric (Mictoryl Pediatric) are detrusor relaxant drugs with antimuscarinic and calcium-modulating properties indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). Propiverine MR is available in 30 mg and 45 mg capsules, taken once daily, for adults with OAB. Propiverine pediatric is an immediate-release formulation (IR) available in 5 mg tablets for children, with body weight-adjusted dosage to be taken twice daily. The manufacturer has submitted a price of 1.39 dollar per 30 mg or 45 mg MR capsule (1.39 dollar per day), and 0.37 dollar per 5 mg IR tablet (0.74 to 2.22 dollar per day). Propiverine IR 15 mg was never marketed in Canada. |
|---|---|
| Physical Description: | 1 online resource (vii, 7 pages) |
| Bibliography: | Includes bibliographical references. |
